Tags

Type your tag names separated by a space and hit enter

Risedronate reduces the risk of first vertebral fracture in osteoporotic women.
Osteoporos Int. 2002; 13(6):501-5.OI

Abstract

Risedronate treatment reduces the risk of vertebral fracture in women with existing vertebral fractures, but its efficacy in prevention of the first vertebral fracture in women with osteoporosis but without vertebral fractures has not been determined. We examined the risk of first vertebral fracture in postmenopausal women who were enrolled in four placebo-controlled clinical trials of risedronate and who had low lumbar spine bone mineral density (BMD) (mean T-score = -3.3) and no vertebral fractures at baseline. Subjects received risedronate 5 mg (n = 328) or placebo (n = 312) daily for up to 3 years; all subjects were given calcium (1000 mg daily), as well as vitamin D supplementation (up to 500 IU daily) if baseline serum 25-hydroxyvitamin D levels were low. The incidence of first vertebral fracture was 9.4% in the women treated with placebo and 2.6% in those treated with risedronate 5 mg (risk reduction of 75%, 95% confidence interval 37% to 90%; P = 0.002). The number of patients who would need to be treated to prevent one new vertebral fracture is 15. When subjects were stratified by age, similar significant reductions were observed in patients with a mean age of 64 years (risk reduction of 70%, 95% CI 8% to 90%; P = 0.030) and in those with a mean age of 76 years (risk reduction of 80%, 95% CI 7% to 96%; P = 0.024). Risedronate treatment therefore significantly reduces the risk of first vertebral fracture in postmenopausal women with osteoporosis, with a similar magnitude of effect early and late after the menopause.

Authors+Show Affiliations

Creighton University, Omaha, Nebraska 68131, USA. rheaney@creighton.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12107665

Citation

Heaney, R P., et al. "Risedronate Reduces the Risk of First Vertebral Fracture in Osteoporotic Women." Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, vol. 13, no. 6, 2002, pp. 501-5.
Heaney RP, Zizic TM, Fogelman I, et al. Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporos Int. 2002;13(6):501-5.
Heaney, R. P., Zizic, T. M., Fogelman, I., Olszynski, W. P., Geusens, P., Kasibhatla, C., Alsayed, N., Isaia, G., Davie, M. W., & Chesnut, C. H. (2002). Risedronate reduces the risk of first vertebral fracture in osteoporotic women. Osteoporosis International : a Journal Established as Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 13(6), 501-5.
Heaney RP, et al. Risedronate Reduces the Risk of First Vertebral Fracture in Osteoporotic Women. Osteoporos Int. 2002;13(6):501-5. PubMed PMID: 12107665.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Risedronate reduces the risk of first vertebral fracture in osteoporotic women. AU - Heaney,R P, AU - Zizic,T M, AU - Fogelman,I, AU - Olszynski,W P, AU - Geusens,P, AU - Kasibhatla,C, AU - Alsayed,N, AU - Isaia,G, AU - Davie,M W, AU - Chesnut,C H,3rd PY - 2002/7/11/pubmed PY - 2002/7/31/medline PY - 2002/7/11/entrez SP - 501 EP - 5 JF - Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA JO - Osteoporos Int VL - 13 IS - 6 N2 - Risedronate treatment reduces the risk of vertebral fracture in women with existing vertebral fractures, but its efficacy in prevention of the first vertebral fracture in women with osteoporosis but without vertebral fractures has not been determined. We examined the risk of first vertebral fracture in postmenopausal women who were enrolled in four placebo-controlled clinical trials of risedronate and who had low lumbar spine bone mineral density (BMD) (mean T-score = -3.3) and no vertebral fractures at baseline. Subjects received risedronate 5 mg (n = 328) or placebo (n = 312) daily for up to 3 years; all subjects were given calcium (1000 mg daily), as well as vitamin D supplementation (up to 500 IU daily) if baseline serum 25-hydroxyvitamin D levels were low. The incidence of first vertebral fracture was 9.4% in the women treated with placebo and 2.6% in those treated with risedronate 5 mg (risk reduction of 75%, 95% confidence interval 37% to 90%; P = 0.002). The number of patients who would need to be treated to prevent one new vertebral fracture is 15. When subjects were stratified by age, similar significant reductions were observed in patients with a mean age of 64 years (risk reduction of 70%, 95% CI 8% to 90%; P = 0.030) and in those with a mean age of 76 years (risk reduction of 80%, 95% CI 7% to 96%; P = 0.024). Risedronate treatment therefore significantly reduces the risk of first vertebral fracture in postmenopausal women with osteoporosis, with a similar magnitude of effect early and late after the menopause. SN - 0937-941X UR - https://www.unboundmedicine.com/medline/citation/12107665/Risedronate_reduces_the_risk_of_first_vertebral_fracture_in_osteoporotic_women_ L2 - https://doi.org/10.1007/s001980200061 DB - PRIME DP - Unbound Medicine ER -